Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (B): Business Model Innovation in Vaccine Delivery SWOT Analysis / TOWS Matrix / Weighted SWOT Analysis
Innovation & Entrepreneurship
Strategy / MBA Resources
Case Study SWOT Analysis Solution
Case Study Description of Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (B): Business Model Innovation in Vaccine Delivery
This case explores the difficulties involved in commercialising vaccines in low-income settings. The focus is the dengue vaccine, launched at the end of 2015, which was first commercialised in emerging markets. It considers issues of affordability and distribution, higlighting the need for business model innovation in all industries.
Swot Analysis of "Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (B): Business Model Innovation in Vaccine Delivery" written by Philip Parker, Pierfitte Marion includes – strengths weakness that are internal strategic factors of the organization, and opportunities and threats that Vaccine Dengue facing as an external strategic factors. Some of the topics covered in Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (B): Business Model Innovation in Vaccine Delivery case study are - Strategic Management Strategies, Emerging markets, Health and Innovation & Entrepreneurship.
Some of the macro environment factors that can be used to understand the Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (B): Business Model Innovation in Vaccine Delivery casestudy better are - – increasing inequality as vast percentage of new income is going to the top 1%, competitive advantages are harder to sustain because of technology dispersion, banking and financial system is disrupted by Bitcoin and other crypto currencies, talent flight as more people leaving formal jobs, increasing energy prices, digital marketing is dominated by two big players Facebook and Google, increasing commodity prices,
supply chains are disrupted by pandemic , technology disruption, etc
Introduction to SWOT Analysis of Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (B): Business Model Innovation in Vaccine Delivery
SWOT stands for an organization’s Strengths, Weaknesses, Opportunities and Threats . At Oak Spring University , we believe that protagonist in Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (B): Business Model Innovation in Vaccine Delivery case study can use SWOT analysis as a strategic management tool to assess the current internal strengths and weaknesses of the Vaccine Dengue, and to figure out the opportunities and threats in the macro environment – technological, environmental, political, economic, social, demographic, etc in which Vaccine Dengue operates in.
According to Harvard Business Review, 75% of the managers use SWOT analysis for various purposes such as – evaluating current scenario, strategic planning, new venture feasibility, personal growth goals, new market entry, Go To market strategies, portfolio management and strategic trade-off assessment, organizational restructuring, etc.
SWOT Objectives / Importance of SWOT Analysis and SWOT Matrix
SWOT analysis of Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (B): Business Model Innovation in Vaccine Delivery can be done for the following purposes –
1. Strategic planning using facts provided in Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (B): Business Model Innovation in Vaccine Delivery case study
2. Improving business portfolio management of Vaccine Dengue
3. Assessing feasibility of the new initiative in Innovation & Entrepreneurship field.
4. Making a Innovation & Entrepreneurship topic specific business decision
5. Set goals for the organization
6. Organizational restructuring of Vaccine Dengue
Strengths Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (B): Business Model Innovation in Vaccine Delivery | Internal Strategic Factors
What are Strengths in SWOT Analysis / TOWS Matrix / Weighted SWOT Analysis
The strengths of Vaccine Dengue in Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (B): Business Model Innovation in Vaccine Delivery Harvard Business Review case study are -
Analytics focus
– Vaccine Dengue is putting a lot of focus on utilizing the power of analytics in business decision making. This has put it among the leading players in the industry. The technology infrastructure suggested by Philip Parker, Pierfitte Marion can also help it to harness the power of analytics for – marketing optimization, demand forecasting, customer relationship management, inventory management, information sharing across the value chain etc.
Sustainable margins compare to other players in Innovation & Entrepreneurship industry
– Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (B): Business Model Innovation in Vaccine Delivery firm has clearly differentiated products in the market place. This has enabled Vaccine Dengue to fetch slight price premium compare to the competitors in the Innovation & Entrepreneurship industry. The sustainable margins have also helped Vaccine Dengue to invest into research and development (R&D) and innovation.
Superior customer experience
– The customer experience strategy of Vaccine Dengue in the segment is based on four key concepts – personalization, simplification of complex needs, prompt response, and continuous engagement.
Cross disciplinary teams
– Horizontal connected teams at the Vaccine Dengue are driving operational speed, building greater agility, and keeping the organization nimble to compete with new competitors. It helps are organization to ideate new ideas, and execute them swiftly in the marketplace.
Ability to lead change in Innovation & Entrepreneurship field
– Vaccine Dengue is one of the leading players in its industry. Over the years it has not only transformed the business landscape in its segment but also across the whole industry. The ability to lead change has enabled Vaccine Dengue in – penetrating new markets, reaching out to new customers, and providing different value propositions to different customers in the international markets.
Effective Research and Development (R&D)
– Vaccine Dengue has innovation driven culture where significant part of the revenues are spent on the research and development activities. This has resulted in, as mentioned in case study Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (B): Business Model Innovation in Vaccine Delivery - staying ahead in the industry in terms of – new product launches, superior customer experience, highly competitive pricing strategies, and great returns to the shareholders.
Successful track record of launching new products
– Vaccine Dengue has launched numerous new products in last few years, keeping in mind evolving customer preferences and competitive pressures. Vaccine Dengue has effective processes in place that helps in exploring new product needs, doing quick pilot testing, and then launching the products quickly using its extensive distribution network.
High switching costs
– The high switching costs that Vaccine Dengue has built up over years in its products and services combo offer has resulted in high retention of customers, lower marketing costs, and greater ability of the firm to focus on its customers.
Training and development
– Vaccine Dengue has one of the best training and development program in the industry. The effectiveness of the training programs can be measured in Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (B): Business Model Innovation in Vaccine Delivery Harvard Business Review case study by analyzing – employees retention, in-house promotion, loyalty, new venture initiation, lack of conflict, and high level of both employees and customer engagement.
Diverse revenue streams
– Vaccine Dengue is present in almost all the verticals within the industry. This has provided firm in Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (B): Business Model Innovation in Vaccine Delivery case study a diverse revenue stream that has helped it to survive disruptions such as global pandemic in Covid-19, financial disruption of 2008, and supply chain disruption of 2021.
Ability to recruit top talent
– Vaccine Dengue is one of the leading recruiters in the industry. Managers in the Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (B): Business Model Innovation in Vaccine Delivery are in a position to attract the best talent available. The firm has a robust talent identification program that helps in identifying the brightest.
Operational resilience
– The operational resilience strategy in the Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (B): Business Model Innovation in Vaccine Delivery Harvard Business Review case study comprises – understanding the underlying the factors in the industry, building diversified operations across different geographies so that disruption in one part of the world doesn’t impact the overall performance of the firm, and integrating the various business operations and processes through its digital transformation drive.
Weaknesses Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (B): Business Model Innovation in Vaccine Delivery | Internal Strategic Factors
What are Weaknesses in SWOT Analysis / TOWS Matrix / Weighted SWOT Analysis
The weaknesses of Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (B): Business Model Innovation in Vaccine Delivery are -
Ability to respond to the competition
– As the decision making is very deliberative, highlighted in the case study Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (B): Business Model Innovation in Vaccine Delivery, in the dynamic environment Vaccine Dengue has struggled to respond to the nimble upstart competition. Vaccine Dengue has reasonably good record with similar level competitors but it has struggled with new entrants taking away niches of its business.
Workers concerns about automation
– As automation is fast increasing in the segment, Vaccine Dengue needs to come up with a strategy to reduce the workers concern regarding automation. Without a clear strategy, it could lead to disruption and uncertainty within the organization.
High cash cycle compare to competitors
Vaccine Dengue has a high cash cycle compare to other players in the industry. It needs to shorten the cash cycle by 12% to be more competitive in the marketplace, reduce inventory costs, and be more profitable.
Products dominated business model
– Even though Vaccine Dengue has some of the most successful products in the industry, this business model has made each new product launch extremely critical for continuous financial growth of the organization. firm in the HBR case study - Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (B): Business Model Innovation in Vaccine Delivery should strive to include more intangible value offerings along with its core products and services.
No frontier risks strategy
– After analyzing the HBR case study Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (B): Business Model Innovation in Vaccine Delivery, it seems that company is thinking about the frontier risks that can impact Innovation & Entrepreneurship strategy. But it has very little resources allocation to manage the risks emerging from events such as natural disasters, climate change, melting of permafrost, tacking the rise of artificial intelligence, opportunities and threats emerging from commercialization of space etc.
Interest costs
– Compare to the competition, Vaccine Dengue has borrowed money from the capital market at higher rates. It needs to restructure the interest payment and costs so that it can compete better and improve profitability.
Compensation and incentives
– The revenue per employee as mentioned in the HBR case study Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (B): Business Model Innovation in Vaccine Delivery, is just above the industry average. Vaccine Dengue needs to redesign the compensation structure and incentives to increase the revenue per employees. Some of the steps that it can take are – hiring more specialists on project basis, etc.
Slow to strategic competitive environment developments
– As Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (B): Business Model Innovation in Vaccine Delivery HBR case study mentions - Vaccine Dengue takes time to assess the upcoming competitions. This has led to missing out on atleast 2-3 big opportunities in the industry in last five years.
High dependence on existing supply chain
– The disruption in the global supply chains because of the Covid-19 pandemic and blockage of the Suez Canal illustrated the fragile nature of Vaccine Dengue supply chain. Even after few cautionary changes mentioned in the HBR case study - Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (B): Business Model Innovation in Vaccine Delivery, it is still heavily dependent upon the existing supply chain. The existing supply chain though brings in cost efficiencies but it has left Vaccine Dengue vulnerable to further global disruptions in South East Asia.
High dependence on star products
– The top 2 products and services of the firm as mentioned in the Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (B): Business Model Innovation in Vaccine Delivery HBR case study still accounts for major business revenue. This dependence on star products in has resulted into insufficient focus on developing new products, even though Vaccine Dengue has relatively successful track record of launching new products.
Lack of clear differentiation of Vaccine Dengue products
– To increase the profitability and margins on the products, Vaccine Dengue needs to provide more differentiated products than what it is currently offering in the marketplace.
Opportunities Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (B): Business Model Innovation in Vaccine Delivery | External Strategic Factors
What are Opportunities in the SWOT Analysis / TOWS Matrix / Weighted SWOT Analysis
The opportunities highlighted in the Harvard Business Review case study Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (B): Business Model Innovation in Vaccine Delivery are -
Loyalty marketing
– Vaccine Dengue has focused on building a highly responsive customer relationship management platform. This platform is built on in-house data and driven by analytics and artificial intelligence. The customer analytics can help the organization to fine tune its loyalty marketing efforts, increase the wallet share of the organization, reduce wastage on mainstream advertising spending, build better pricing strategies using personalization, etc.
Harnessing reconfiguration of the global supply chains
– As the trade war between US and China heats up in the coming years, Vaccine Dengue can build a diversified supply chain model across various countries in - South East Asia, India, and other parts of the world. This reconfiguration of global supply chain can help, as suggested in case study, Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (B): Business Model Innovation in Vaccine Delivery, to buy more products closer to the markets, and it can leverage its size and influence to get better deal from the local markets.
Reforming the budgeting process
- By establishing new metrics that will be used to evaluate both existing and potential projects Vaccine Dengue can not only reduce the costs of the project but also help it in integrating the projects with other processes within the organization.
Better consumer reach
– The expansion of the 5G network will help Vaccine Dengue to increase its market reach. Vaccine Dengue will be able to reach out to new customers. Secondly 5G will also provide technology framework to build new tools and products that can help more immersive consumer experience and faster consumer journey.
Use of Bitcoin and other crypto currencies for transactions
– The popularity of Bitcoin and other crypto currencies as asset class and medium of transaction has opened new opportunities for Vaccine Dengue in the consumer business. Now Vaccine Dengue can target international markets with far fewer capital restrictions requirements than the existing system.
Learning at scale
– Online learning technologies has now opened space for Vaccine Dengue to conduct training and development for its employees across the world. This will result in not only reducing the cost of training but also help employees in different part of the world to integrate with the headquarter work culture, ethos, and standards.
Reconfiguring business model
– The expansion of digital payment system, the bringing down of international transactions costs using Bitcoin and other blockchain based currencies, etc can help Vaccine Dengue to reconfigure its entire business model. For example it can used blockchain based technologies to reduce piracy of its products in the big markets such as China. Secondly it can use the popularity of e-commerce in various developing markets to build a Direct to Customer business model rather than the current Channel Heavy distribution network.
Low interest rates
– Even though inflation is raising its head in most developed economies, Vaccine Dengue can still utilize the low interest rates to borrow money for capital investment. Secondly it can also use the increase of government spending in infrastructure projects to get new business.
Lowering marketing communication costs
– 5G expansion will open new opportunities for Vaccine Dengue in the field of marketing communication. It will bring down the cost of doing business, provide technology platform to build new products in the Innovation & Entrepreneurship segment, and it will provide faster access to the consumers.
Using analytics as competitive advantage
– Vaccine Dengue has spent a significant amount of money and effort to integrate analytics and machine learning into its operations in the sector. This continuous investment in analytics has enabled, as illustrated in the Harvard case study Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (B): Business Model Innovation in Vaccine Delivery - to build a competitive advantage using analytics. The analytics driven competitive advantage can help Vaccine Dengue to build faster Go To Market strategies, better consumer insights, developing relevant product features, and building a highly efficient supply chain.
Leveraging digital technologies
– Vaccine Dengue can leverage digital technologies such as artificial intelligence and machine learning to automate the production process, customer analytics to get better insights into consumer behavior, realtime digital dashboards to get better sales tracking, logistics and transportation, product tracking, etc.
Finding new ways to collaborate
– Covid-19 has not only transformed business models of companies in Innovation & Entrepreneurship industry, but it has also influenced the consumer preferences. Vaccine Dengue can tie-up with other value chain partners to explore new opportunities regarding meeting customer demands and building a rewarding and engaging relationship.
Changes in consumer behavior post Covid-19
– Consumer behavior has changed in the Innovation & Entrepreneurship industry because of Covid-19 restrictions. Some of this behavior will stay once things get back to normal. Vaccine Dengue can take advantage of these changes in consumer behavior to build a far more efficient business model. For example consumer regular ordering of products can reduce both last mile delivery costs and market penetration costs. Vaccine Dengue can further use this consumer data to build better customer loyalty, provide better products and service collection, and improve the value proposition in inflationary times.
Threats Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (B): Business Model Innovation in Vaccine Delivery External Strategic Factors
What are Threats in the SWOT Analysis / TOWS Matrix / Weighted SWOT Analysis
The threats mentioned in the HBR case study Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (B): Business Model Innovation in Vaccine Delivery are -
Backlash against dominant players
– US Congress and other legislative arms of the government are getting tough on big business especially technology companies. The digital arm of Vaccine Dengue business can come under increasing regulations regarding data privacy, data security, etc.
Learning curve for new practices
– As the technology based on artificial intelligence and machine learning platform is getting complex, as highlighted in case study Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (B): Business Model Innovation in Vaccine Delivery, Vaccine Dengue may face longer learning curve for training and development of existing employees. This can open space for more nimble competitors in the field of Innovation & Entrepreneurship .
High dependence on third party suppliers
– Vaccine Dengue high dependence on third party suppliers can disrupt its processes and delivery mechanism. For example -the current troubles of car makers because of chip shortage is because the chip companies started producing chips for electronic companies rather than car manufacturers.
Barriers of entry lowering
– As technology is more democratized, the barriers to entry in the industry are lowering. It can presents Vaccine Dengue with greater competitive threats in the near to medium future. Secondly it will also put downward pressure on pricing throughout the sector.
Regulatory challenges
– Vaccine Dengue needs to prepare for regulatory challenges as consumer protection groups and other pressure groups are vigorously advocating for more regulations on big business - to reduce inequality, to create a level playing field, to product data privacy and consumer privacy, to reduce the influence of big money on democratic institutions, etc. This can lead to significant changes in the Innovation & Entrepreneurship industry regulations.
New competition
– After the dotcom bust of 2001, financial crisis of 2008-09, the business formation in US economy had declined. But in 2020 alone, there are more than 1.5 million new business applications in United States. This can lead to greater competition for Vaccine Dengue in the Innovation & Entrepreneurship sector and impact the bottomline of the organization.
Technology disruption because of hacks, piracy etc
– The colonial pipeline illustrated, how vulnerable modern organization are to international hackers, miscreants, and disruptors. The cyber security interruption, data leaks, etc can seriously jeopardize the future growth of the organization.
Increasing wage structure of Vaccine Dengue
– Post Covid-19 there is a sharp increase in the wages especially in the jobs that require interaction with people. The increasing wages can put downward pressure on the margins of Vaccine Dengue.
Easy access to finance
– Easy access to finance in Innovation & Entrepreneurship field will also reduce the barriers to entry in the industry, thus putting downward pressure on the prices because of increasing competition. Vaccine Dengue can utilize it by borrowing at lower rates and invest it into research and development, capital expenditure to fortify its core competitive advantage.
Trade war between China and United States
– The trade war between two of the biggest economies can hugely impact the opportunities for Vaccine Dengue in the Innovation & Entrepreneurship industry. The Innovation & Entrepreneurship industry is already at various protected from local competition in China, with the rise of trade war the protection levels may go up. This presents a clear threat of current business model in Chinese market.
High level of anxiety and lack of motivation
– the Great Resignation in United States is the sign of broader dissatisfaction among the workforce in United States. Vaccine Dengue needs to understand the core reasons impacting the Innovation & Entrepreneurship industry. This will help it in building a better workplace.
Capital market disruption
– During the Covid-19, Dow Jones has touched record high. The valuations of a number of companies are way beyond their existing business model potential. This can lead to capital market correction which can put a number of suppliers, collaborators, value chain partners in great financial difficulty. It will directly impact the business of Vaccine Dengue.
Consumer confidence and its impact on Vaccine Dengue demand
– There is a high probability of declining consumer confidence, given – high inflammation rate, rise of gig economy, lower job stability, increasing cost of living, higher interest rates, and aging demography. All the factors contribute to people saving higher rate of their income, resulting in lower consumer demand in the industry and other sectors.
Weighted SWOT Analysis of Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (B): Business Model Innovation in Vaccine Delivery Template, Example
Not all factors mentioned under the Strengths, Weakness, Opportunities, and Threats quadrants in the SWOT Analysis are equal. Managers in the HBR case study Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (B): Business Model Innovation in Vaccine Delivery needs to zero down on the relative importance of each factor mentioned in the Strengths, Weakness, Opportunities, and Threats quadrants.
We can provide the relative importance to each factor by assigning relative weights. Weighted SWOT analysis process is a three stage process –
First stage for doing weighted SWOT analysis of the case study Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (B): Business Model Innovation in Vaccine Delivery is to rank the strengths and weaknesses of the organization. This will help you to assess the most important strengths and weaknesses of the firm and which one of the strengths and weaknesses mentioned in the initial lists are marginal and can be left out.
Second stage for conducting weighted SWOT analysis of the Harvard case study Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (B): Business Model Innovation in Vaccine Delivery is to give probabilities to the external strategic factors thus better understanding the opportunities and threats arising out of macro environment changes and developments.
Third stage of constructing weighted SWOT analysis of Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (B): Business Model Innovation in Vaccine Delivery is to provide strategic recommendations includes – joining likelihood of external strategic factors such as opportunities and threats to the internal strategic factors – strengths and weaknesses. You should start with external factors as they will provide the direction of the overall industry. Secondly by joining probabilities with internal strategic factors can help the company not only strategic fit but also the most probably strategic trade-off that Vaccine Dengue needs to make to build a sustainable competitive advantage.
Feel free to connect with us if you need business research.
You can download Excel Template of Case Study Solution & Analysis of Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (B): Business Model Innovation in Vaccine Delivery